J 2001

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

OLSSON, AG, P PAUCIULLO, Vladimír SOŠKA, P LULEY, RE PIETERS et. al.

Basic information

Original name

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

Name (in English)

Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.

Authors

OLSSON, AG, P PAUCIULLO, Vladimír SOŠKA, P LULEY, RE PIETERS, G BRODA and B PALACIOS

Edition

Clin Ther, UNITED STATES, ELSEVIER, 2001, 0149-2918

Other information

Type of outcome

Článek v odborném periodiku

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.721

Organization unit

Faculty of Medicine

Keywords in English

Fluvastatin; hypercholesterolemia
Změněno: 16/3/2011 13:38, prof. MUDr. Vladimír Soška, CSc.

Abstract

ORIG EN

V originále

The purpose of this study was to compare the lipid-lowering efficacy and tolerability of fluvastatin ER (80 mg once daily) versus fluvastatin immediate-release (IR) (40 mg once or twice daily). Of the 1183 patients enrolled, 695 were randomly assigned to treatment 346 to fluvastatin ER 80 mg QPM, 174 to fluvastatin IR 40 mg QPM, and 175 to fluvastatin IR 40 mg BID. Patients were well matched between groups, with a mean age of 56 years and body mass index of 27 kg/m2; 56.0% of patients (389/695) were female and 97.7% (679/695) were white. Fluvastatin ER 80 mg QPM lowered LDL-C levels significantly

In English

The purpose of this study was to compare the lipid-lowering efficacy and tolerability of fluvastatin ER (80 mg once daily) versus fluvastatin immediate-release (IR) (40 mg once or twice daily). Of the 1183 patients enrolled, 695 were randomly assigned to treatment 346 to fluvastatin ER 80 mg QPM, 174 to fluvastatin IR 40 mg QPM, and 175 to fluvastatin IR 40 mg BID. Patients were well matched between groups, with a mean age of 56 years and body mass index of 27 kg/m2; 56.0% of patients (389/695) were female and 97.7% (679/695) were white. Fluvastatin ER 80 mg QPM lowered LDL-C levels significantly